Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect - PubMed
4 hours ago
- #brain-metastases
- #NSCLC
- #filamentous-phage
- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with brain metastases occurring in 24% to 40% of advanced NSCLC patients.
- Traditional treatments for brain metastases (surgery, radiotherapy) often cause neurocognitive impairment and brain edema, while chemotherapy struggles to penetrate the CNS.
- Third-generation EGFR-TKI drugs can cross the blood-brain barrier but are limited to patients with specific driver genes.
- Immunotherapy shows potential for NSCLC with brain metastases but has adverse effects limiting clinical use.
- Filamentous phages are promising bio-nanomaterials due to biosafety, solubility, and targeted delivery capabilities, reducing systemic toxicity.
- Two core applications of filamentous phages: (i) phage display-derived targeting peptides and (ii) intact engineered phages as delivery scaffolds.
- Filamentous phages can prolong circulation time, reduce toxicity, and cross the BBB, enabling targeted delivery of chemotherapeutics and siRNA to NSCLC cells.
- Potential for clinical translation includes personalized therapy via patient-specific peptide screening.
- Filamentous phage-based nanocarriers may improve the quality of life for NSCLC patients with brain metastases.